KYNB

Kyntra Bio, Inc. Common Stock

4.65

USD

-0.07

-1.48%

Oct 29, 15:59 UTC -4

Closed

Pre-Market

4.84

+0.19

+4.11%

Kyntra Bio, Inc. Common Stock (KYNB) Earnings

KYNB Earnings Reports

Positive Surprise Ratio

KYNB beat 2 of 4 last estimates.

50%

Next Report

Date of Next Report

Nov 09, 2026

Estimate for Q3 26 (Revenue/ EPS)

$1.87M

-$3.80

Implied change from Q2 26 (Revenue/ EPS)

-226.81%

-18.98%

Implied change from Q3 25 (Revenue/ EPS)

+73.71%

+16.92%

Kyntra Bio, Inc. Common Stock earnings per share and revenue

On Aug 13, 2026, KYNB reported earnings of -4.69 USD per share (EPS) for Q2 26, missing the estimate of -3.24 USD, resulting in a -44.45% surprise. Revenue reached -1474000, compared to an expected 2.05 million, with a -172.01% difference. The market reacted with a +0.14% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -3.80 USD, with revenue projected to reach 1.87 million USD, implying an decrease of -18.98% EPS, and decrease of -226.81% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Gilead Sciences Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.24

Actual

$2.54

Surprise

+13.66%

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Incyte Genomics Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$3.92

Actual

-$3.60

Surprise

+8.33%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

Ligand Pharmaceuticals Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.42

Actual

$2.67

Surprise

+9.91%

Fortrea Holdings Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.22

Actual

$0.28

Surprise

+26.53%

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

FAQ

What were Kyntra Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Kyntra Bio, Inc. Common Stock reported EPS of -$4.69, missing estimates by -44.45%, and revenue of $-1.47M, -172.01% below expectations.

How did the market react to Kyntra Bio, Inc. Common Stock's Q2 2026 earnings?

The stock price moved up 0.14%, changed from $7.04 before the earnings release to $7.05 the day after.

When is Kyntra Bio, Inc. Common Stock expected to report next?

The next earning report is scheduled for Nov 09, 2026.

What are the forecasts for Kyntra Bio, Inc. Common Stock's next earnings report?

Based on -- analysts, Kyntra Bio, Inc. Common Stock is expected to report EPS of -$3.80 and revenue of $1.87M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.